Related Experiment Video
Updated: Sep 27, 2026
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Angiogenesis inhibition with TNP-470, 2-methoxyestradiol, and paclitaxel in experimental pancreatic carcinoma
E Ryschich1, J Werner, M M Gebhard
1Department of Surgery, University of Heidelberg, Heidelberg, Germany.
Introduction:
Inhibition of tumor angiogenesis is a novel therapeutic modality for various malignancies.
Aim:
To investigate the effect of different antiangiogenic agents (TNP-470, 2-methoxyestradiol, and paclitaxel) on growth and neovascularization of experimental pancreatic cancer.
Methodology:
In 25 male Lewis rats, tumor induction was achieved by orthotopic and subcutaneous tumor fragment implantation of ductlike pancreatic cancer DSL6A. Four weeks after tumor implantation, the animals were randomly treated with TNP-470, 2-methoxyestradiol, or paclitaxel. After 2 weeks of antiangiogenic therapy, total tumor volume, vital tumor surface, vascular density, and apoptosis were measured.
Results:
Total tumor volume and vital tumor surface were not significantly different in any of the treatment groups. Similarly, vascular density and apoptosis were not altered by treatment with the various angiogenesis inhibitors at the specific doses used.
Conclusion:
We conclude that in contrast to many earlier studies, angiogenesis inhibition by a single-drug application and by the doses used in the present model did not reveal a favorable therapeutic effect on pancreatic cancer DSL6A. The combination of different angiogenesis inhibitors or higher doses might be more effective.
Insights
Antiangiogenic agents TNP-470, 2-methoxyestradiol, and paclitaxel did not significantly impact experimental pancreatic cancer growth or neovascularization. Higher doses or drug combinations may be necessary for therapeutic effects in pancreatic cancer treatment.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Tumor angiogenesis inhibition is a promising therapeutic strategy for various cancers.
- Investigating novel antiangiogenic agents is crucial for advancing cancer treatment.
- Pancreatic cancer remains a challenging malignancy with limited effective therapies.
Purpose of the Study:
- To evaluate the efficacy of TNP-470, 2-methoxyestradiol, and paclitaxel as antiangiogenic agents.
- To assess the impact of these agents on tumor growth and neovascularization in experimental pancreatic cancer.
- To determine the effects on tumor volume, vital surface area, vascular density, and apoptosis.
Main Methods:
- Experimental pancreatic cancer (DSL6A) was induced in Lewis rats via orthotopic and subcutaneous implantation.
- Animals received treatment with TNP-470, 2-methoxyestradiol, or paclitaxel for two weeks.
- Tumor volume, vital tumor surface, vascular density, and apoptosis were quantified post-treatment.
Main Results:
- No significant differences were observed in total tumor volume or vital tumor surface across treatment groups.
- Vascular density and apoptosis levels remained unaltered by the administered antiangiogenic agents at the tested doses.
- Single-agent antiangiogenic therapy at these doses did not demonstrate a therapeutic benefit in this pancreatic cancer model.
Conclusions:
- Single-agent antiangiogenic therapy with TNP-470, 2-methoxyestradiol, or paclitaxel showed no favorable therapeutic effect on experimental pancreatic cancer DSL6A.
- The study suggests that combination therapy or higher doses of angiogenesis inhibitors may be required for efficacy.
- Further research is warranted to explore optimized antiangiogenic strategies for pancreatic cancer.
